[Form 4] Shattuck Labs, Inc. Insider Trading Activity
Insider purchase reported: Clay B. Siegall, a director of Shattuck Labs, Inc. (STTK), participated in a private placement that closed on August 25, 2025, acquiring 128,054 shares of common stock and accompanying warrants to buy up to 128,054 additional shares. The combined price for one share plus its accompanying warrant was $0.8677. The warrants have an exercise price of $1.0846 and are exercisable from issuance until 30 days after the company publicly announces certain Phase 1 SL-325 trial data and the planned Phase 2 design.
Acquisto da parte di un insider segnalato: Clay B. Siegall, membro del consiglio di amministrazione di Shattuck Labs, Inc. (STTK), ha partecipato a un collocamento privato chiuso il 25 agosto 2025, acquisendo 128.054 azioni ordinaria e warrant correlati per acquistare fino a 128.054 azioni aggiuntive. Il prezzo combinato per una azione e il relativo warrant era $0.8677. I warrant hanno un prezzo di esercizio di $1.0846 e sono esercitabili dalla data di emissione fino a 30 giorni dopo che la societ脿 avr脿 reso pubblici determinati dati del trial di fase 1 su SL-325 e il progetto pianificato della fase 2.
Compra de insider reportada: Clay B. Siegall, director de Shattuck Labs, Inc. (STTK), particip贸 en una colocaci贸n privada que se cerr贸 el 25 de agosto de 2025, adquiriendo 128.054 acciones ordinarias y warrants asociados para comprar hasta 128.054 acciones adicionales. El precio combinado por una acci贸n m谩s su warrant fue de $0.8677. Los warrants tienen un precio de ejercicio de $1.0846 y pueden ejercitarse desde su emisi贸n hasta 30 d铆as despu茅s de que la compa帽铆a anuncie p煤blicamente ciertos datos del ensayo de fase 1 de SL-325 y el dise帽o planificado de la fase 2.
雮措秬鞛� 毵れ垬 氤搓碃: Shattuck Labs, Inc.(STTK) 鞚挫偓鞚� Clay B. Siegall鞚� 2025雲� 8鞗� 25鞚� 毵堦皭霅� 靷 氚滍枆鞐� 彀胳棳頃橃棳 氤错喌欤� 128,054欤�鞕� 於旉皜搿� 128,054欤�旯岇 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸鸽ゼ 旆摑頄堨姷雼堧嫟. 欤检嫕 1欤检檧 頃措嫻 鞗岆煱韸胳潣 瓴绊暕 臧�瓴╈潃 $0.8677鞓�鞀惦媹雼�. 鞗岆煱韸胳潣 頄夓偓 臧�瓴╈潃 $1.0846鞚措┌, 氚滍枆 鞁滌爯攵�韯� 須岇偓臧� SL-325鞚� 1靸� 鞁滍棙 雿办澊韯� 鞚茧秬鞕� 瓿勴殟霅� 2靸� 靹り硠毳� 瓿店皽 氚滍憸頃� 頉� 30鞚� 鞚措偞旯岇 頄夓偓頃� 靾� 鞛堨姷雼堧嫟.
Achat d'initi茅 signal茅 : Clay B. Siegall, administrateur de Shattuck Labs, Inc. (STTK), a particip茅 脿 un placement priv茅 cl么tur茅 le 25 ao没t 2025, acqu茅rant 128 054 actions ordinaires et des bons de souscription permettant d'acheter jusqu'脿 128 054 actions suppl茅mentaires. Le prix combin茅 pour une action et son warrant associ茅 茅tait de $0.8677. Les warrants ont un prix d'exercice de $1.0846 et sont exer莽ables depuis leur 茅mission jusqu'脿 30 jours apr猫s que la soci茅t茅 aura publi茅 certains r茅sultats de l'essai de phase 1 sur le SL-325 et le plan de conception de la phase 2.
Insider-Kauf gemeldet: Clay B. Siegall, ein Direktor von Shattuck Labs, Inc. (STTK), nahm an einer Privatplatzierung teil, die am 25. August 2025 geschlossen wurde, und erwarb 128.054 Aktien des Stammkapitals sowie dazugeh枚rige Warrants zum Kauf von bis zu 128.054 zus盲tzlichen Aktien. Der Kombinationspreis f眉r eine Aktie plus den dazugeh枚rigen Warrant betrug $0.8677. Die Warrants haben einen Aus眉bungspreis von $1.0846 und sind von der Ausgabe an bis 30 Tage nach der 枚ffentlichen Bekanntgabe bestimmter Phase鈥�1鈥慏aten zu SL鈥�325 und des geplanten Phase鈥�2鈥慏esigns aus眉bbar.
- Director participation in financing (128,054 shares) demonstrates insider alignment with the company's financing round
- Warrants exercisable upon clinical milestone announcement aligns potential equity upside with concrete trial data disclosure
- Warrants have a higher exercise price ($1.0846) than the combined purchase price per share-plus-warrant ($0.8677), requiring future value appreciation to realize gains
- Exercisability is contingent on specific clinical disclosures, which may delay or limit the ability to exercise the warrants
Insights
TL;DR: A director bought equity and warrants in a private placement at modest prices, aligning ownership with potential clinical milestones.
The reporting shows a direct acquisition of 128,054 common shares and matching warrants at a combined purchase price of $0.8677 per share-plus-warrant. Warrants carry a $1.0846 exercise price and are exercisable until a defined post-clinical-data announcement window. This transaction increases the director's direct equity stake and ties warrant exercisability to clinical progress, which links potential insider participation to product development catalysts.
TL;DR: Director participation in a private placement is disclosed properly; terms restrict warrant exercise to specific trial disclosures.
The Form 4 discloses compliance with Section 16 reporting and notes purchase under a securities purchase agreement dated August 4, 2025, with a close on August 25, 2025. The filing identifies the director explicitly and shows direct ownership following the transaction. The warrant exercisability condition is clearly tied to public disclosure of Phase 1 SL-325 data and Phase 2 design, which is a defined milestone-based condition rather than a time-only expiration.
Acquisto da parte di un insider segnalato: Clay B. Siegall, membro del consiglio di amministrazione di Shattuck Labs, Inc. (STTK), ha partecipato a un collocamento privato chiuso il 25 agosto 2025, acquisendo 128.054 azioni ordinaria e warrant correlati per acquistare fino a 128.054 azioni aggiuntive. Il prezzo combinato per una azione e il relativo warrant era $0.8677. I warrant hanno un prezzo di esercizio di $1.0846 e sono esercitabili dalla data di emissione fino a 30 giorni dopo che la societ脿 avr脿 reso pubblici determinati dati del trial di fase 1 su SL-325 e il progetto pianificato della fase 2.
Compra de insider reportada: Clay B. Siegall, director de Shattuck Labs, Inc. (STTK), particip贸 en una colocaci贸n privada que se cerr贸 el 25 de agosto de 2025, adquiriendo 128.054 acciones ordinarias y warrants asociados para comprar hasta 128.054 acciones adicionales. El precio combinado por una acci贸n m谩s su warrant fue de $0.8677. Los warrants tienen un precio de ejercicio de $1.0846 y pueden ejercitarse desde su emisi贸n hasta 30 d铆as despu茅s de que la compa帽铆a anuncie p煤blicamente ciertos datos del ensayo de fase 1 de SL-325 y el dise帽o planificado de la fase 2.
雮措秬鞛� 毵れ垬 氤搓碃: Shattuck Labs, Inc.(STTK) 鞚挫偓鞚� Clay B. Siegall鞚� 2025雲� 8鞗� 25鞚� 毵堦皭霅� 靷 氚滍枆鞐� 彀胳棳頃橃棳 氤错喌欤� 128,054欤�鞕� 於旉皜搿� 128,054欤�旯岇 毵れ垬頃� 靾� 鞛堧姅 鞗岆煱韸鸽ゼ 旆摑頄堨姷雼堧嫟. 欤检嫕 1欤检檧 頃措嫻 鞗岆煱韸胳潣 瓴绊暕 臧�瓴╈潃 $0.8677鞓�鞀惦媹雼�. 鞗岆煱韸胳潣 頄夓偓 臧�瓴╈潃 $1.0846鞚措┌, 氚滍枆 鞁滌爯攵�韯� 須岇偓臧� SL-325鞚� 1靸� 鞁滍棙 雿办澊韯� 鞚茧秬鞕� 瓿勴殟霅� 2靸� 靹り硠毳� 瓿店皽 氚滍憸頃� 頉� 30鞚� 鞚措偞旯岇 頄夓偓頃� 靾� 鞛堨姷雼堧嫟.
Achat d'initi茅 signal茅 : Clay B. Siegall, administrateur de Shattuck Labs, Inc. (STTK), a particip茅 脿 un placement priv茅 cl么tur茅 le 25 ao没t 2025, acqu茅rant 128 054 actions ordinaires et des bons de souscription permettant d'acheter jusqu'脿 128 054 actions suppl茅mentaires. Le prix combin茅 pour une action et son warrant associ茅 茅tait de $0.8677. Les warrants ont un prix d'exercice de $1.0846 et sont exer莽ables depuis leur 茅mission jusqu'脿 30 jours apr猫s que la soci茅t茅 aura publi茅 certains r茅sultats de l'essai de phase 1 sur le SL-325 et le plan de conception de la phase 2.
Insider-Kauf gemeldet: Clay B. Siegall, ein Direktor von Shattuck Labs, Inc. (STTK), nahm an einer Privatplatzierung teil, die am 25. August 2025 geschlossen wurde, und erwarb 128.054 Aktien des Stammkapitals sowie dazugeh枚rige Warrants zum Kauf von bis zu 128.054 zus盲tzlichen Aktien. Der Kombinationspreis f眉r eine Aktie plus den dazugeh枚rigen Warrant betrug $0.8677. Die Warrants haben einen Aus眉bungspreis von $1.0846 und sind von der Ausgabe an bis 30 Tage nach der 枚ffentlichen Bekanntgabe bestimmter Phase鈥�1鈥慏aten zu SL鈥�325 und des geplanten Phase鈥�2鈥慏esigns aus眉bbar.
FAQ
What did Clay B. Siegall purchase in the STTK Form 4?
What price did the STTK private placement use?
What is the warrant exercise price reported in the STTK Form 4?
When can the warrants be exercised?
When was the transaction completed?
